Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

November 19, 2018

Study Completion Date

November 19, 2018

Conditions

Healthy

Interventions

DRUG

meropenem-vaborbactam

Meropenem-Vaborbactam being studied for effects on TQT

DRUG

Placebo

DRUG

Moxifloxacin

Active Comparator

Trial Locations (1)

Pharmaron Cpc, Inc, Baltimore

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

INDUSTRY

NCT03564158 - Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers | Biotech Hunter | Biotech Hunter